Literature DB >> 29672299

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Tang Liu1,2,3,4, Zuyun Yan1, Yong Liu4, Edwin Choy3, Francis J Hornicek2, Henry Mankin3, Zhenfeng Duan2.   

Abstract

BACKGROUND/AIMS: Metastasis is the major cause of death in patients with osteosarcoma. There is an urgent need to identify molecular markers that promote metastasis. Cluster of differentiation 44 is a receptor for hyaluronic acid (HA) and HA-binding has been proven to participate in various biological tumor activities, including tumor progression and metastasis.
METHODS: We performed a meta-analysis to investigate the relationship between CD44 expression, survival, and metastasis in patients with osteosarcoma. We then utilized the CRISPR-Cas9 system to specifically silence CD44 in highly metastatic human osteosarcoma cells (MNNG/HOS and 143B) and further determined the functional effects of CD44 knockout in these cells.
RESULTS: The meta-analysis demonstrated that a high level of CD44 may predict poor survival and higher potential of metastasis in patients with osteosarcoma. The expression of CD44 in highly metastatic human osteosarcoma cell lines was efficiently blocked by CRISPR-Cas9. When CD44 was silenced, the proliferation and spheroid formation of these osteosarcoma cells was inhibited under 3-D culture conditions. Furthermore, the migratory and invasive functions were also impaired in these highly metastatic osteosarcoma cells.
CONCLUSION: These results suggest that developing new strategies to target CD44 in osteosarcoma may prevent metastasis and improve the clinical outcome of osteosarcoma patients.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  CD44; CRISPR-Cas9; Gene therapy; Meta-analysis; Metastases; Osteosarcoma

Mesh:

Substances:

Year:  2018        PMID: 29672299     DOI: 10.1159/000489072

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  12 in total

Review 1.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

2.  Establishment and application of a human osteosarcoma U-2OS cell line that can stably express Cas9 protein.

Authors:  Yonghua Zhou; Yingjie Li; Yu Zhang; Zilin Yi; Minggui Jiang
Journal:  Mol Cell Biochem       Date:  2022-04-20       Impact factor: 3.842

Review 3.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

Review 4.  Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors.

Authors:  Wei Liu; Shubin Wang; Binhui Lin; Wei Zhang; Guangrong Ji
Journal:  BMC Musculoskelet Disord       Date:  2021-02-05       Impact factor: 2.362

Review 5.  The role of extracelluar matrix in osteosarcoma progression and metastasis.

Authors:  Juncheng Cui; Dylan Dean; Francis J Hornicek; Zhiwei Chen; Zhenfeng Duan
Journal:  J Exp Clin Cancer Res       Date:  2020-09-04

6.  Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis.

Authors:  Peng Gao; Guanghui Ren
Journal:  Aging (Albany NY)       Date:  2021-10-11       Impact factor: 5.682

Review 7.  Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment.

Authors:  Duoli Xie; Zhuqian Wang; Jie Li; De-An Guo; Aiping Lu; Chao Liang
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

Review 8.  CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.

Authors:  Enrique Fernández-Tabanera; Raquel M Melero-Fernández de Mera; Javier Alonso
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

9.  CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.

Authors:  Monserrat Gerardo-Ramírez; Friederike L Keggenhoff; Vanessa Giam; Diana Becker; Marco Groth; Nils Hartmann; Beate K Straub; Helen Morrison; Peter R Galle; Jens U Marquardt; Peter Herrlich; Monika Hartmann
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

10.  Antioxidant and Cytotoxic Activities of Kudzu Roots and Soy Molasses against Pediatric Tumors and Phytochemical Analysis of Isoflavones Using HPLC-DAD-ESI-HRMS.

Authors:  Saied A Aboushanab; Vadim A Shevyrin; Grigory P Slesarev; Vsevolod V Melekhin; Anna V Shcheglova; Oleg G Makeev; Elena G Kovaleva; Ki Hyun Kim
Journal:  Plants (Basel)       Date:  2022-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.